Cite
HARVARD Citation
Mavratzas, A. et al. (2019). Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. Breast. pp. 22-28. [Online].